25/04/2024  19:06:01 Chg. - Volume Bid17:35:23 Demandez à17:35:23 Capitalisation boursière Dividende Y. Rapport P/E
268.25USD - 2,462
Chiffrre d'affaires: 173,778.10
-Bid taille: - -Ask la taille: - 152.45 Mrd.USD 3.05% 22.58

Description de l'entreprise

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
 

Conseil d'administration & Conseil de surveillance

PDG
Robert Bradway
Conseil d'administration
Peter H. Griffith, Annalisa Pizzarello, Anton Rabushka, Arleen Paulino, Darryl Sleep, David A. Piacquad, David M. Reese, Esteban Santos, Gilles Marrache, Ian Thompson, Jean-Charles Soria, Jerry Murry, Jonathan Graham, Judy Gawlik Brown, Lori Johnston, Mark J. Taisey, Mike Zahigian, Murdo Gordon, Nancy Grygiel, Rachna Khosla, Raymond Deshaies, Rob Lenz, Susan Sweeney, Victoria H. Blatter
Conseil de surveillance
Robert A. Bradway, Amy E. Miles, Brian J. Druker, Charles M. Holley Jr., Ellen J. Kullman, Greg C. Garland, Michael V. Drake, R. Sanders Williams, Robert A. Eckert, Ronald D. Sugar, S. Omar Ishrak, Tyler Jacks, Wanda M. Austin
 

Données de l'entreprise

Nom: Amgen Inc.
Adresse: One Amgen Center Drive,Thousand Oaks, CA 91320-1799, USA
Téléphone: +1-805-447-1000
Fax: +1-805-447-1010
Courriel: investor.relations@amgen.com
Internet: www.amgen.com
Industrie: Healthcare
Secteur: Medical Products
Sous-secteur: Advanced Medical Devices
Fin de l'exercice financier: 31/12
Flotte libre: 76.20%
IPO date: 17/06/1983

Relations avec les investisseurs

Nom: -
Téléphone IR: +1-805-447-1060
IR-Fax: -
E-mail IR: investor.relations@amgen.com

Calendrier de l'entreprise

CW 47 | 18/11/2024 Record Date
CW 47 | 18/11/2024 Ex-Dividend
CW 50 | 09/12/2024 Dividend Payment
 

Principaux actionnaires

Autres
 
71.83%
Vanguard Group Inc
 
9.15%
State Street Corp
 
5.50%
Primecap Management Co/Ca/
 
2.72%
Morgan Stanley
 
2.69%
Geode Capital Management, Llc
 
2.30%
Charles Schwab Investment Management Inc
 
1.94%
Wells Fargo & Company/Mn
 
1.40%
Capital Research Global Investors
 
1.25%
Autres
 
1.22%